- $315.99m
- $1.24bn
- $0.89m
ProKidney Corp expected to post a loss of 16 cents a share - Earnings Preview
ProKidney Corp reports results for the quarter ended in June - Earnings Summary
ProKidney Corp expected to post a loss of 39 cents a share - Earnings Preview
ProKidney Corp expected to post a loss of 39 cents a share - Earnings Preview
Brief: Prokidney Appoints Bruce Culleton, MD, As Executive Vice President, Clinical Development & Commercialization
U.S. STOCKS ON THE MOVE-Rio Tinto, BurgerFi International, Aclaris Therapeutics
ProKidney Corp up on deal to buy manufacturing plant in Greensboro
Brief: Prokidney Announces Purchase Of Manufacturing Facility In Greensboro, Nc
Brief: Prokidney Reports First Quarter Financial Results
Brief: Prokidney Reports Fourth Quarter Financial Results And Recent Corporate Highlights
U.S. STOCKS ON THE MOVE-Tesla, Eton Pharma, Jack Henry & Associates
U.S. STOCKS ON THE MOVE-Levi Strauss, Salesforce, Eli Lilly
U.S. STOCKS ON THE MOVE-ProKidney Corp, Dentsply Sirona, Lipella Pharmaceuticals Inc
ProKidney Corp jumps as therapy shows promise in kidney disease trial
Brief: ProKidney Announces Publication Of Trial Design For Clinical Trial
U.S. STOCKS ON THE MOVE-Energy firms, Tesla, Activision Blizzard
Brief: Prokidney Corp Reports Q3 Loss Of $0.13 Per Share
Brief: Prokidney Receives Allowance From The Uk Medicines And Healthcare Products Regulatory Agency (Mhra) For Proact 1 (Regen-006) And EMA Scientific Advice On Phase 3 Protocols Of React For Diabetic Chronic Kidney Disease
Brief: Prokidney Corp. Reports Second Quarter 2022 Financial Results And Provides Business Update